Compare Amylx Pharmaceuticals Inc (AMLX) vs Global X Defense Tech ETF (SHLD) Price & Performance

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

SHLD (Global X Defense Tech ETF) trades at $69.04, up 1.86% with bullish technical signals from moving averages but overbought RSI readings. The ETF benefits from institutional accumulation and positive sentiment around global defense spending increases. Recent news highlights multiple institutional investors increasing positions, while technical analysis shows strong support at $68 and resistance at $70.

Outlook remains positive given geopolitical tensions driving defense budgets higher, though overbought conditions suggest potential near-term consolidation. Key risks include political uncertainty and valuation concerns after recent gains. The ETF offers diversified exposure to defense technology with institutional confidence supporting the long-term thesis.